Protein test may predict immunotherapy success in advanced melanoma
NCT ID NCT07436390
First seen Feb 28, 2026 · Last updated May 13, 2026 · Updated 15 times
Summary
This study looked at 132 people with advanced melanoma to see if levels of a protein called interferon-gamma (IFN-γ) in tumor tissue and blood could predict how well they would respond to first-line immunotherapy drugs. Researchers also explored whether gut bacteria play a role in treatment outcomes. The goal is to help doctors personalize treatment and avoid giving ineffective therapies to patients who are unlikely to benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia
Conditions
Explore the condition pages connected to this study.